Advancing Cutaneous Toxicity Assessment with a Long-Term Human Ex Vivo Skin Platform: Applications Across Therapeutic Modalities
2:15 pm - Wednesday 26th August 2026
- Introducing an advanced ex vivo human skin platform that maintains native skin architecture and immune responsiveness for up to ~1 month across diverse human donors
- Demonstrating sustained, disease-relevant inflammatory responses and pharmacologic modulation through longitudinal histopathology, soluble biomarkers, and transcriptomics
- Applying the platform across diverse therapeutic modalities and biological targets using dose-ranging and multimodal endpoints to investigate target-associated effects and the onset and progression of inflammatory, tissue stress, and toxicity responses
- Advancing a human-relevant NAM to bridge the gap between preclinical models and clinical translation, support earlier safety decisions, and help de-risk therapies before patient exposure
